Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma

JCO Precis Oncol. 2018;2018:PO.18.00135. doi: 10.1200/PO.18.00135. Epub 2018 Nov 8.
No abstract available